Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05420909 · ClinicalTrials.gov registry record
A Study of Overall Survival in Participants With Metastatic Colorectal Cancer (mCRC)
A clinical trial of Metastatic Colorectal Cancer (mCRC), sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- 124
- Enrollment target
- 1
- Study location
NCT05420909: Completed study of Metastatic Colorectal Cancer (mCRC), sponsored by Bristol-Myers Squibb.
NCT05420909 is a study of Metastatic Colorectal Cancer (mCRC) that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 124 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05420909, a study of Metastatic Colorectal Cancer (mCRC), has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- 124 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to estimate the overall survival (OS) for US participants diagnosed with metastatic colorectal cancer (mCRC) by using Flatiron Health's individual patient level data.
Conditions Studied
Study Locations (1)
New Jersey
- Local Institution - Princeton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 124 participants |
| Start Date | 2019-01-28 |
| Est. Completion | 2019-04-01 |
What the finished NCT05420909 record still lists
NCT05420909 is an observational study that tracks outcomes without assigning an intervention. The registered 124 participants enrollment target is mid-sized for trials with a published cap.
The record links to 1 condition, with Metastatic Colorectal Cancer (mCRC) appearing as the primary indexed condition, and to 0 interventions.
NCT05420909 reports a single indexed study location in New Jersey.
Frequently Asked Questions
What is clinical trial NCT05420909 about?
NCT05420909 is a clinical study titled "A Study of Overall Survival in Participants With Metastatic Colorectal Cancer (mCRC)". The purpose of this study is to estimate the overall survival (OS) for US participants diagnosed with metastatic colorectal cancer (mCRC) by using Flatiron Health's individual patient level data.
What is the current status of trial NCT05420909?
This trial is currently completed. The enrollment target is 124 participants. The study started on 2019-01-28. Estimated completion is 2019-04-01.
What conditions does trial NCT05420909 study?
This clinical trial studies the following conditions: Metastatic Colorectal Cancer (mCRC).
Who is sponsoring clinical trial NCT05420909?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05420909 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Colorectal Cancer (mCRC)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 2 Study of Leronlimab in Combination With TAS-102 + Bevacizumab in Previously Treated Participants With mCRC
RECRUITING · Phase 2
-
PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarcinoma, or Metastatic Adrenocortical Carcinoma
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523014 · 124 participants · Phase 2
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas
- NCT02670707 · 124 participants · Phase 3
Vinblastine/Prednisone Versus Single Therapy With Cytarabine for Langerhans Cell Histiocytosis (LCH)
- NCT02830724 · 124 participants · Phase 1
Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers
- NCT04748809 · 124 participants · NA
Effect of Anti-inflammatory Diet in Rheumatoid Arthritis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI